# Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures

> **NCT00610454** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 25 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Levetiracetam

## Key facts

- **NCT ID:** NCT00610454
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-08
- **Final completion:** 2004-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610454, "Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00610454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*